PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.\', \'Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Division of Core Diagnostics, Abbott Japan LLC, Tokyo, Japan.\', \'Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: mizoue@hosp.ncgm.go.jp.\', \'Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(22)00196-710.1016/j.vaccine.2022.02.052
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 35183384
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35183384>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35183384>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all